Get to know our clinical trials
Clinical trial of ANV600 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
THIS CLINICAL TRIAL HAS TWO PARTS AND, DEPENDING ON WHEN IT IS PROPOSED TO YOU, YOU WILL PARTICIPATE IN EITHER: ¿ THE FIRST PART (PHASE 1), WHICH AIMS TO LEARN ABOUT THE SAFETY OF DIFFERENT DOSES OF ANV600 WHEN GIVEN ALONE OR IN COMBINATION WITH PEMBROLIZUMAB AND SELECT THE BEST DOSE OF ANV600, OR ¿ THE SECOND PART (PHASE 2), WHICH WILL USE THE DOSE OF ANV600 SELECTED IN PHASE 1 TO FURTHER INVESTIGATE ITS EFFICACY AND SAFETY WHEN GIVEN ALONE OR IN COMBINATION WITH PEMBROLIZUMAB. BOTH PARTS WILL ALSO INVESTIGATE WHAT YOUR BODY DOES WITH THE DRUG, I.E. HOW IT ABSORBS, DISTRIBUTES AND ELIMINATES THE TRIAL DRUG.
Technical Summary
- FIRST PHASE I/II, OPEN-LABEL, MULTICENTER HUMAN STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF ANV600 IN MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
- Code EudraCT: 2023-509633-39
- Protocol number: ANV600-001
- Promoter: Anaveon AG
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.